- 1. Emma Back MeTA Consultant MeTA country guidance note
Movingtowards medicines data transparency, joint analysis and
evidence-based policies to improve access to medicines 8 December
2009
2. Purpose of the guidance note
- Toprovideadviceandguidanceto MeTA pilot countries specifically
national Secretariats and multi-stakeholder groups as they take
steps towards establishing a process of routine disclosure of key
medicines data.
- To provide sometoolsandexamplesto aid this process, sharecase
studiesandlessonsfrom different countries, and identify potential
sources of TA.
- The note will help to ensurestandardization of reportingacross
MeTA countries, which will in turn aidcomparison, monitoring and
evaluation .
3. Proposed content
- Recap of MeTA pilot phase goals and principles
- Purpose of guidance note in this context
- Phased approach towards increasing transparency,
[accountability,] and evidence-based policy and practice; an
ongoing cycle:
- Setting parameters; agreeing reporting format; agreeing
process
- Data collection / submission; data assessment
- Multi-stakeholder discussion of the data
- Data use - including for comms, advocacy and policy
development
- Using the phased approach in practice
- Securing additional support
4. Questions for you
- Does the step-wise approach make sense?
- Will the proposed format of the guidance note give you what you
need?
- What else would you like to see in the note? What do you need
most guidance on? TA priorities?
- Do you have any case studies or lessons you would like to share
through the guidance note?
- Any data collection / disclosure / reporting formats?